Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals.

Each week, we highlight 5 key developments or headlines from healthcare that you need to know—whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine. This week's top stories include new phase 2 data on NS002 for the treatment of 

, the publication of the 2026 Heart Disease and Stroke Statistics from the American Heart Association (AHA), new clinical guidance from the American College of Chest Physicians (CHEST) on biologic management in severe 

, findings from a national survey on topical steroid use in dermatology, and data from 2 phase 3 studies of amlitelimab for the treatment of patients ≥ 12 years of age with moderate-to-severe 

With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here’s your quick dive into the top stories for the week of January 18, 2026—let’s jump in!

Phase 2 Data Show NS002 Intranasal Epinephrine Acts Faster Than EpiPen

On January 20, 2026, Nasus Pharma announced positive interim results from its phase 2 clinical study of NS002, the Company's investigational intranasal epinephrine powder formulation for the treatment of anaphylaxis. Results showed NS002 achieved faster absorption, higher peak concentrations, and greater early epinephrine exposure compared to intramuscular EpiPen® autoinjector.

AHA 2026 Heart Disease and Stroke Statistics: Progress and Pitfalls, With Latha Palaniappan, MD, MS

The 2026 Heart Disease and Stroke Statistics from the AHA spotlight heart disease and stroke as being among the leading causes of death in the US, with heart disease remaining the leading cause of death and stroke moving up to the #4 spot.

New CHEST Recommendations Guide Biologic Use for Severe Asthma

CHEST released a new clinical guideline on biologic management in severe asthma, offering 7 evidence-based recommendations to provide a framework for pulmonologists, allergists, and immunologists to implement in their own practice. The document examines existing biologics and provides evidence-based recommendations for which biologics to consider for different patient populations.

Topical Steroid Concerns in Dermatology Highlighted in Nationwide Survey

ON January 21, 2026, Arcutis Biotherapeutics announced results of 

Skin Insights: Steroid Perceptions in Chronic Inflammatory Skin Diseases

, a nationwide survey of adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. Results showed nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being treated with topical steroids are concerned about side effects, and nearly 8 in 10 adults and parents agreed that their or their child's treatment plan focuses on reactively “taming a flare” rather than proactive long-term solutions. Additionally, when their skin condition is uncontrolled, nearly all adults and children experience emotional, mental, and daily life challenges

Amlitelimab Effective, Safe for Atopic Dermatitis in Patients 12 Years and Older

On January 23, 2026, Sanofi announced results from 2 global phase 3 studies – SHORE and COAST 2 – of amlitelimab, a fully human non-T cell depleting monoclonal antibody that selectively targets OX40-ligand, for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis. In these two phase 3 studies amlitelimab was well-tolerated and the safety profile was consistent with previously reported data.

Articles

Nasus Pharma's phase 2 study of NS002 shows faster absorption and higher peak concentrations than EpiPen for anaphylaxis treatment. The AHA's 2026 statistics highlight heart disease as the leading cause of death, with stroke now fourth. CHEST's new guidelines provide evidence-based recommendations for biologic management in severe asthma. A nationwide survey reveals significant concerns about topical steroid side effects in dermatology. Sanofi's phase 3 studies demonstrate amlitelimab's efficacy and safety for treating moderate-to-severe atopic dermatitis in patients aged 12 and older.

Stay updated with the latest healthcare breakthroughs, including new phase 2/3 data and updated asthma guidelines, in this week’s essential news roundup.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

The HCPFive: Top News for Healthcare Providers from the Week of 01/18

Mauro D'Amato, PhD, is Ikerbasque Research Professor and head of the Gastrointestinal Genetics Lab at CIC bioGUNE.

From Physiology to Genetics: A New Lens on Gut Motility, With Mauro D’Amato, PhD

Gut motility plays a central role in digestive health, yet the biological mechanisms that regulate how frequently the bowel moves and why this varies so widely among individuals remain incompletely understood. This challenge is especially pronounced in disorders of gut–brain interaction, such as irritable bowel syndrome (IBS), where symptoms like constipation and diarrhea reflect underlying dysmotility but arise from complex, multifactorial processes.

, Mauro D’Amato, PhD, Ikerbasque Research Professor and head of the Gastrointestinal Genetics Lab at CIC bioGUNE, and colleagues took an unconventional approach to this challenge, examining gut motility as a physiological trait. Specifically, they analyzed stool frequency as a measurable outcome across large populations, with the goal of identifying genetic mechanisms that influence bowel movement patterns and could ultimately be targeted therapeutically.

“The problem in studying these diseases, I do genetics, so I try to identify what could be the eventual genetic causes or partial cause of these diseases, is that they're very complex. There are so many factors playing a role,” D’Amato explained to 

. “Instead of looking at the actual disease, we had the idea to look at the physiology, with the idea that if we identify genes that are relevant to gut motility, we identify mechanisms relevant to gut motility, and then eventually we can target these mechanisms to cure or treat alterations of the of the gut motility and peristalsis.”

He and a team of investigators performed a multiancestry genome-wide association study (GWAS) meta-analysis of stool frequency in 268,606 European and East Asian individuals. Heritability and genetic correlations with other traits were estimated, and Mendelian randomization was used to test causal relationships. GWAS signals were fine-mapped and functionally annotated to prioritize candidate genes and pathways. Findings implicating thiamine metabolism were followed-up with dietary interaction analyses in UK Biobank.

Results showed strong genetic correlations with gastrointestinal and psychiatric disorders (rg=0.18–0.47), and causal effects on IBS. Novel correlations with cardiovascular traits (rg=0.12–0.14) were supported by drug signature enrichment analyses.

They identified 21 independent loci, including 10 novel signals implicating bile acid synthesis (

). Fine-mapping converged on vitamin B1 metabolism, highlighting single-variant causal effects at 

, a phosphate exporter essential for thiamine activation.

In 98,449 UK Biobank participants, thiamine intake was positively associated with SF (

 genotype score significantly modulated this effect (

“I’ve already heard people saying ‘Oh, well, how much vitamin B? What should I eat every day now?’ We're not there yet, at least this is not what we do in the lab,” D’Amato explained, describing the need for future animal studies and eventual human clinical trials to determine whether vitamin B1 supplementation can meaningfully improve real-world outcomes.

He additionally pointed to study findings highlighting both established and unexplored compounds behind the regulation of gut motility, the latter of which offers a potential next wave of candidates to be tested.

Editors’ Note: D’Amato reports no relevant disclosures.

Díaz-Muñoz C, Bozzarelli I, Lopera-Maya EA

Genetic dissection of stool frequency implicates vitamin B1 metabolism and other actionable pathways in the modulation of gut motility. 

CIC bioGUNE. DNA ties gut motility to vitamin B1. EurekAlert! January 20, 2026. Accessed January 23, 2026. 

https://www.eurekalert.org/news-releases/1112772

Videos

D’Amato explains his research on the biological mechanisms that control bowel movements and vitamin B1’s potential role in gut motility.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Irritable Bowel Syndrome

On the HCPLive irritable bowel syndrome page, resources on the topics of medical news and expert insight into IBS can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBS, IBD, and more.

Logan Briggs is a senior urology resident at Mayo Clinic Arizona.

Kidney Cancer Survivors Benefit From Increased Psychological Support, With Logan Briggs, MD

Psychological support demonstrates significantly positive clinical outcomes for kidney cancer survivors enrolled in prehabilitation or rehabilitation programs, according to a new scoping review.

“This study is the first systematic search of the literature on prehabilitation, rehabilitation, exercise, psychological support, or nutrition interventions for KC survivors or their caregivers,” wrote Logan Briggs, a study investigator and senior urology resident at Mayo Clinic Arizona, and colleagues. “The broad scope of the search is a strength in that it provides a comprehensive review.”

The findings support strengthening psychological support services as part of comprehensive cancer care for patients with kidney cancer, while also acknowledging potential benefits associated with tailored exercise programs and preoperative carbohydrate supplementation.

“Across the board, these interventions improved anxiety and depression, and in many cases, also enhanced quality of life, sleep, post-traumatic symptoms, and even physical functioning,” explained Logan Briggs, in an interview with 

 “About half of the studies included patients with advanced cancer, which may contribute to higher anxiety levels, though the benefits of psychological support were consistent. The takeaway for clinicians is that any type of psychologist, psychiatrist, therapist, or social worker can provide meaningful support for these patients.”

As Briggs noted, prehabilitation and rehabilitation interventions for kidney cancer survivors remain largely unexplored, with substantial gaps in the literature. To date, only 18 randomized controlled trials have evaluated these approaches. Notably, no studies have assessed cost-effectiveness or stratified outcomes by socioeconomic or demographic characteristics.

To address these gaps, Briggs and colleagues conducted a scoping review of all 18 randomized controlled trials involving kidney cancer survivors enrolled in prehabilitation or rehabilitation programs. Interventions included psychological support, exercise-based programs, and nutritional or pharmacologic components. For each study, they recorded whether interventions yielded statistically significant positive, negative or no significant difference for the outcomes of interest.

The systematic search identified 2774 unique participants, including 706 patients or survivors with kidney cancer. Of the 18 trials, 6 exclusively enrolled patients with kidney cancer, while the remaining 12 included kidney cancer survivors as a subset of a broader cancer population.

Across intervention types, investigators found cognitive behavioral therapy, mindfulness meditation, yoga, body scanning, positive expressive writing, Morita therapy, and mindful eating were associated with positive clinical outcomes. Among the 7 trials focused solely on psychological support, 6 demonstrated improvement. Additionally, all 3 studies combining psychological support with exercise showed benefit.

In contrast, nutrition was a notably understudied area. Only 1 trial demonstrated significant findings, showing that preoperative carbohydrate drinks administered the night before and 2 hours prior to radical nephrectomy improved quality of life and reduced postoperative weight loss. Beyond this, evidence to guide nutritional interventions for this population was limited.

Exercise interventions varied widely, ranging from high-intensity interval training to step-count monitoring using wearable devices. Some studies evaluated exercise alone, while others combined physical activity with psychological support.

“One key finding is that well-designed exercise programs, those that are tailored to the patient, follow the FIT principles (frequency, intensity, time, type), and have a clear rationale, tend to produce the best outcomes,” said Briggs.

He described this concept as the “therapeutic validity” of an exercise intervention. Using the Therapeutic Content Scale developed by Hoojeboom, studies scoring >6 out of 9 were considered to demonstrate strong therapeutic validity. Investigators observed increased validity scores correlated with improved patient outcomes, including VO₂ max, step counts, and mobility measures such as the Timed Up and Go test.

Editor’s note: Briggs reports relevant disclosures with Delfina, Tolmar, Consens, and others.

Briggs LG, Parke SC, Gill VS, et al. Exercise, nutrition, and psychological support for kidney cancer: a scoping review. 

. Published online January 18, 2026. doi:

Hoogeboom TJ, Kousemaker MC, van Meeteren NL, et al. i-CONTENT tool for assessing therapeutic quality of exercise programs employed in randomised clinical trials. 

https://doi.org/10.1136/bjsports-2019-101630

The first scoping review of kidney cancer pre/ rehabilitation suggests psychological support outdoes exercise and nutrition. 

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

 Kidney Cancer Survivors Benefit From Increased Psychological Support, With Logan Briggs, MD

Vivian Fonseca, MD, is professor of medicine, assistant dean for clinical research, and the Tullis-Tulane Alumni Chair in Diabetes at Tulane University School of Medicine.

CAPTAIN-T2D: New Trial Investigates Treating Elevated Cortisol in T2D, With Vivian Fonseca, MD

The phase 2 Clofutriben And Placebo Against INtractable Type 2 Diabetes (CAPTAIN-T2D) trial, investigating clofutriben to improve glycemic control and metabolic health in patients with difficult-to-control 

 and elevated cortisol, has officially enrolled its first patient.

CAPTAIN-T2D directly follows positive results from the CATALYST trial in 2025, which saw 136 patients with T2D and hypercortisolism randomly assigned in a 2:1 ratio to either mifepristone 300-900 mg once daily (n = 91) or placebo (n = 45) for 24 weeks. The primary endpoint was the change in HbA1c, which worked out to a -1.32% difference compared to placebo. Additionally, patients receiving mifepristone saw reductions in body weight and waist circumference.

“So, what we want to do now in CAPTAIN-T2D is to use another approach at treating this elevated cortisol,” Vivian Fonseca, MD, professor of medicine, assistant dean for clinical research, and the Tullis-Tulane Alumni Chair in Diabetes at Tulane University School of Medicine, told 

 in an exclusive interview. “In this instance, we’re using an 11-beta hydroxysteroid dehydrogenase inhibitor, which uses a completely different approach from mifepristone. You’re addressing intracellular cortisol by blocking this enzyme that leads to conversion of the inactive cortisone to cortisol, and so you’re decreasing cortisol activity in the tissues.”

CAPTAIN-T2D is a 2-part trial – the first part will see patients with poorly controlled T2D despite being on multiple medications screened for elevated cortisol using an overnight dexamethasone suppression test. This period will last between 5 and 9 weeks for most participants.

Eligible patients will then be randomly assigned to either clofutriben 0.2 mg, 2 mg, 6 mg, or 12 mg, or a placebo control, all of which will be administered daily. This second part will last for 24 weeks, with a follow-up phone call 4 weeks after the final dose.

To be eligible for inclusion, patients must be ≥18 years old with an HbA1c ≥7.5% documented within 3 months prior to screening. Additionally, patients require ≥1 of the following:

Diabetes complications – retinopathy, nephropathy, neuropathy, 

Hypertension needing ≥2 adequately dosed AHMs

Adequately dosed basal or basal plus prandial insulin on top of ≥1 other ADM

Adequately dosed incretin agonists on top of ≥1 other ADM

Evidence or history of osteoporosis or non-traumatic fracture

Established diagnosis of a neoplastic source of hypercortisolism and have failed, are ineligible for, or declined surgery.

CAPTAIN-T2D has 2 primary endpoints: the first is the percentage of patients with both morning serum cortisol >1.8 mg/dL and morning plasma dexamethasone >-140 ng/dL after a single dexamethasone 1 mg dose taken the night prior. The second endpoint involves glycated hemoglobin A1c percent change from baseline to week 24 by treatment. Secondary endpoints include fasting plasma glucose change from baseline and the frequency of treatment-emergent adverse events.

The trial is expected to enroll a total of 1500 patients and is planned to end in June of 2028.

“We’ve begun to use this method a lot in other conditions, such as cancer: you find a particular defect, and you treat it with therapy that’s specifically targeted to that defect,” Fonseca said. “Unfortunately, we don’t have much of that in diabetes. We’ve been using a one-glove-fits-all approach, giving everybody every new medication that comes along, and the success has been mixed. Overall, control is better than it was 20 years ago, but it’s still not right, and I think identifying abnormalities could help with better outcomes.”

Editor’s Note: Fonseca reports disclosures with Abbott, AstraZeneca, Novo Nordisk, Sanofi-Aventis, Eli Lilly, Bayer, and others.

Sparrow Pharmaceuticals. Sparrow Pharmaceuticals Announces First Patient Enrolled in Phase 2b Clinical Trial Evaluation Clofutriben for Difficult-to-Control Type 2 Diabetes. 

. January 6, 2026. Accessed January 23, 2026. 

https://www.biospace.com/press-releases/sparrow-pharmaceuticals-announces-first-patient-enrolled-in-phase-2b-clinical-trial-evaluating-clofutriben-for-difficult-to-control-type-2-diabetes

DeFronzo RA, Fonseca V, Aroda VR, et al. Inadequately controlled type 2 diabetes and hypercortisolism: Improved glycemia with mifepristone treatment. 

Sparrow Pharmaceuticals. Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) (CAPTAIN-T2D). ClinicalTrials.gov Identifier: NCT07296484. Updated January 22, 2026. Accessed January 23, 2026. 

https://clinicaltrials.gov/study/NCT07296484?term=NCT07296484&rank=1

Fonseca explains the structure and goals of the ongoing trial, which has enrolled its first patient to clofutriben treatment against hard-to-control T2D.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

Autoclaved Peanuts Reduce IgE Binding, Improve Tolerability, With Casey Cohen, PhD

Heat- and pressure-based food processing is not new to allergy research, but new data suggest it may meaningfully alter peanut allergenicity in ways that traditional cooking cannot. In a recent interview with 

, Casey Cohen, PhD, of McGill University, discussed findings from a study demonstrating that autoclaving peanuts, a process combining high temperature, pressure, and moisture, substantially reduces immunoglobulin E (IgE) binding and improves oral tolerability in individuals with a 

“The way people eat peanuts is often roasted peanuts if they're eating peanut butter or just roasted peanuts,” Cohen said. “Or sometimes they boil peanuts in different places of the world, often in Asia. Autoclaving is rather untraditional…the process of autoclaving is used for sterilization. What we found is that it's actually changing the proteins in a different way. It's not just using heat, but the presence of water is changing them differently. It’s actually taking these proteins, breaking them down, not completely, but enough, where we have a lot of fragments, and we think that that is what is introducing different forms of peanut proteins to the immune system. That is not happening with say, boiled or roasted peanut.”

The study evaluated how autoclaving peanuts at 130°C and 2.4 atmospheres for 30 minutes alters peanut proteins compared with raw or roasted preparations. Using mass spectrometry-based proteomics, the investigators showed that autoclaving extensively fragments major peanut allergens, including Ara h 1 and Ara h 2, and completely degrades Ara h 8. These molecular changes translated into a 74% reduction in peanut-specific IgE binding in sera from highly allergic patients compared with raw peanuts.

Clinically, the effects were notable. In skin prick testing of 41 peanut-allergic participants, autoclaved peanut extract produced significantly smaller wheal sizes than standard commercial extract (median 5 mm vs 10 mm; 

 <.001). Although responses were heterogeneous, patients with the greatest wheal size reductions tended to have lower IgE levels to peanut (

 <.05), suggesting a potential role for autoclaved extracts in phenotyping peanut allergy risk. However, Cohen said this remains exploratory.

All 10 peanut-allergic participants undergoing an oral food challenge (OFC) tolerated the maximum cumulative dose of autoclaved peanut (444 mg), equivalent to ≥ 1 whole peanut, with only mild to moderate symptoms. In contrast, all participants reacted to blanched peanuts at much lower doses (median 9 mg), often requiring treatment, including epinephrine.

Cohen cautioned clinicians against extrapolating these findings directly to patient practice. Autoclaved peanuts are not ready for home use, nor should patients attempt self-experimentation. It is uncertain whether any patient with a food allergy can tolerate autoclaved peanuts.

“What is more interesting, we believe, is that we can actually use this autoclave peanut as a starting substrate for immunotherapy,” Cohen said. “Right now, a lot of people who are allergic to peanuts severely will have to start with incredibly small amounts of peanuts. It's… smaller than my pinky nail. In that case, it's hard to be consistent. We get a lot of variability, and the peanut proteins themselves are a lot more rigid and [a] lot more likely to induce a more dangerous reaction. By autoclaving the peanuts, we think it'll give us more leeway. We can start at a higher dose of autoclaving peanuts, especially if there's no dangerous symptoms coming with it, and then we can work our way up to maybe, eventually, transfer over to the regular, traditional peanut.”

Cohen CG, Toscano-Rivero D, Ahmed EA, et al. Autoclaved Peanuts Exhibit Reduced Immunoglobulin E Binding and Improved Oral Tolerability. 

. Published online January 6, 2026. doi:10.1111/all.70208

New data show heat- and pressure-treated peanuts significantly reduce IgE binding, skin test reactivity, and oral challenge severity in allergic patients.

Food Allergy

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Carly Maucione, MD, a resident physician at Washington University in St. Louis

Study investigator Carly Maucione, MD, discusses how artificial intelligence could support laboratory workflows while emphasizing education as a near-term solution.

Hematology

Blending Education, Machine Learning to Detect IV Fluid Contaminated CBCs, With Carly Maucione, MD

This first episode of 2026 highlights ways to advocate for change in healthcare, empowering each other and patients while navigating systemic challenges.

The Medical Sisterhood, with Mona Shahriari, MD

The Medical Sisterhood, hosted by Mona Shahriari, MD, is a podcast dedicated to empowering female physicians by providing a platform for shared experiences, mentorship, and support. 

Each episode delves into the unique challenges women in medicine face, including work-life balance, leadership roles, and overcoming gender biases. Shahriari aims to inspire women to lead fulfilling professional and personal lives on their own terms through candid discussions and expert interviews. 

e as we foster a community where women can uplift and support each other in achieving their goals!

Podcasts

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

The Medical Sisterhood: Advocacy and Systemic Change, With Kristi Hawley, DO

Spyridon Fortis, MD, from the division of pulmonary, critical care, and occupational medicine at the University of Iowa Hospital and Clinics.

Fortis discusses new data that challenge the use of bronchodilator response as a tool for distinguishing asthma from COPD.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Bronchodilator Response Predicts COPD Risk, With Spyridon Fortis, MD

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

However, key secondary endpoints, including measures of erythema, were not met in all analyses.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Niels Lund, MSc is the vice president of Changing Diabetes at Novo Nordisk.

Lund discusses a recent study detailing the comparatively lower greenhouse gas emissions caused by preventive care versus diabetes management.

Managing Prediabetes Lowers Carbon Footprint Compared to T2D Care, With Niels Lund, MSc

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

GRI-0621 shows promise as a safe, effective treatment for idiopathic pulmonary fibrosis, improving biomarkers and lung function in a Phase 2a trial.

Pulmonary Fibrosis

GRI-0621 Well-Tolerated, Shows Positive Biomarker and FVC Data in IPF

In these new phase 3b/4 data from LEVEL UP, findings on switching from dupilumab to upadacitinib in patients with atopic dermatitis are explored.

LEVEL UP: New Data on Switching from Dupilumab to Upadacitinib in Atopic Dermatitis

Diane MacDougall, MS, is the vice president of science and research at the Family Heart Foundation.

MacDougall discusses the Family Heart Foundation’s recent study indicating that very few adults with ASCVD are receiving guideline-directed therapy.

Dyslipidemia

LDL-C Management is Dangerously Low Among US Adults With ASCVD, With Diane MacDougall, MS

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center.

Reau and Brown discuss recent research in hepatitis B, C, and D, including use of statins, GLP-1s, and more.

Hepatology

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

Liver Lineup: Updates & Unfiltered Insights

Introducing Liver Lineup: Updates & Unfiltered Insights — an exciting new podcast delivering timely, candid perspectives on the most pressing topics in the fast-moving world of hepatology. Created by Nancy Reau, MD, and Kimberly Brown, MD, and hosted by HCPLive, this series dives into the cutting edge of liver disease research, clinical care, and real-world practice.

Liver Lineup: Advances, Gaps, and What’s Next in Viral Hepatitis

This summary of the 2026 Maui Derm Conference highlights some of the sessions and interviews to look forward to.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Latest News

The HCPFive: Top News for Healthcare Providers from the Week of 01/18

From Physiology to Genetics: A New Lens on Gut Motility, With Mauro D’Amato, PhD

Kidney Cancer Survivors Benefit From Increased Psychological Support, With Logan Briggs, MD

CAPTAIN-T2D: New Trial Investigates Treating Elevated Cortisol in T2D, With Vivian Fonseca, MD

Autoclaved Peanuts Reduce IgE Binding, Improve Tolerability, With Casey Cohen, PhD